Galectin Therapeutics reports preliminary phase Ib data on GR-MD-02 in advanced melanoma Sep. 21, 2018
European Commission approves Braftovi with Mektovi for advanced melanoma with BRAFV600 mutation Sep. 21, 2018
Mesoblast reports survival outcomes through day 180 in phase III study of remestemcel-L Sep. 21, 2018
Further studies planned after first-in-human trial of respiratory disease candidate OATD-01 Sep. 21, 2018
RSS